Altasciences Chosen By Virpax To Support The Development Of A New Drug To Prevent Spread Of Flu-Like Viruses
Portfolio Pulse from Benzinga Newsdesk
Altasciences has been chosen by Virpax Pharmaceuticals (NASDAQ:VRPX) to conduct preclinical studies for the development of AnQlar, a nanoparticle intended to prevent the spread of negatively charged viruses such as COVID-19 and influenza. The project, in development since 2022, has completed safety assessments and a cardiovascular study. The final step will be a bioanalytical sample analysis.
September 21, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Virpax Pharmaceuticals is partnering with Altasciences for the development of AnQlar, a drug aimed at preventing the spread of viruses. This could potentially boost Virpax's portfolio and market position.
The partnership with Altasciences for the development of AnQlar could potentially enhance Virpax's product portfolio and strengthen its market position. If successful, AnQlar could address a significant market need, especially in the context of the ongoing pandemic. This could have a positive impact on Virpax's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100